DocWire News Editors

DocwireNews

<a href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm628121.htm">The U.S. Food and Drug Administration (FDA) announced</a> new measures to advance the development of biosimilars in a letter from Commissioner Scott Gottlieb, MD. &ldquo;Not all parts of the pharmaceutical market have been equally open to competition from more affordable products,&rdquo; he wrote. &ldquo;This is especially true for biologic medicines, which are &hellip; increasingly the backbone of modern therapy.&rdquo;While patent issues surrounding biosimilars continue, the FDA released four guidance documents on the topics in an effort to maintain efficient regulatory processes. Two of the guidance documents provide &ldquo;greater clarity on scientific and regulatory considerations for the development of biosimilar and interchangeable products.&rdquo; The other two documents identify how the FDA will implement a transition of these products from the drug pathway to the biologics pathway. According to the documents, the FDA seeks to transition marketing approval for biologics products to biologic licenses starting in March 2020.In the documents, the FDA addresses the use of limited distribution systems in order to delay or derail access to reference product samples that biosimilars need for testing. &ldquo;While the limited distribution programs can have a role in promoting patient safety, too many branded products are still misusing these programs as rhetorical smokescreens to hide anti-competitive behavior,&rdquo; said Dr. Gottlieb. &ldquo;We&rsquo;re not going to be partners to these deceptions.&rdquo;The FDA said it will review study protocols from biosimilar applicants to assess whether their protocols contain comparable safety protections to those in the Risk Evaluation and Mitigation Strategies (REMS) for the reference product. The FDA will issue a letter to the reference product holder informing them that comparable protections exist, and that the FDA will not consider it to be a violation of the branded drug company&rsquo;s REMS to provide the biosimilar sponsor with a sufficient quantity of the reference product to perform testing necessary to support its biosimilar application. &ldquo;We&rsquo;re actively evaluating how we can make it easier for biosimilar manufacturers to use reference products from outside the United States, where prices may be cheaper and reference products more accessible,&rdquo; said Dr. Gottlieb.&ldquo;I know the pace of progress has disappointed some,&rdquo; he said. &ldquo;I&rsquo;m not discouraged. I believe it will take time for this market to mature. But that doesn&rsquo;t mean we don&rsquo;t face critical challenges. And it doesn&rsquo;t mean that we have the right policy framework to realize these opportunities. There&rsquo;s more that we need to be doing &ndash; all of us.&rdquo;In the past year, the FDA approved seven biosimilar products, for a total of 15 approved products. In addition, there are currently more than 60 biosimilar development programs ongoing.

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

FDA Statement on New Biosimilar Framework

Oncology

The U.S. Food and Drug Administration (FDA) announced new measures to advance the development of biosimilars in a letter from Commissioner Scott Gottlieb, MD. “Not all parts ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe